Resverlogix (RVX) has initiated the first Brazilian and a second Canadian site for its Phase 2b clinical trial for COVID-19 treatment. The study aims to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Donald J. McCaffrey, President & CEO of Resverlogix sat down with Shoran Devi to discuss the study.
MIAMI and TORONTO, Sept. 26, 2024 /PRNewswire/ -- Sekur Private Data Ltd. (OTCQB: SWISF ) (CSE: SKUR) (FRA: GDT0) ("Sekur" or the...
Rakovina Therapeutics has obtained exclusive rights to compounds from the Enki™ platform and the option to license validated drug candidates
ZUNVEYL targets symptoms to provide long-lasting benefits to cognitive and global function and the ability to perform daily activities.
© 2023 Frontier Merchant Capital Group. All Rights Reserved.
תגובות